Prognostic Value and Immunological Role of CBX7 in Lung Adenocarcinoma.

IF 2.2 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current molecular medicine Pub Date : 2025-04-24 DOI:10.2174/0115665240374044250416021616

Lingzheng Yang, Yutang Huang, Wenlu Mo, Lanxiang Wu, Chunjie Wen

{"title":"Prognostic Value and Immunological Role of CBX7 in Lung Adenocarcinoma.","authors":"Lingzheng Yang, Yutang Huang, Wenlu Mo, Lanxiang Wu, Chunjie Wen","doi":"10.2174/0115665240374044250416021616","DOIUrl":null,"url":null,"abstract":"Background: Chromobox 7 (CBX7) has been implicated in the progression of various malignant tumors, but its clinical relevance in lung adenocarcinoma (LUAD) remains poorly understood. This study aimed to investigate the expression, prognostic value, biological functions, and immunological role of CBX7 in LUAD.Methods: CBX7 expression in LUAD and adjacent normal tissues was analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Kaplan-Meier curves and Cox risk regression evaluated prognostic significance. Various algorithms assessed the correlation between CBX7 and immune microenvironment. The expression of CBX7 in LUAD tissues was detected by RT-qPCR, western blotting, and immunohistochemistry. The function of CBX7 in LUAD was further investigated by in vitro and in vivo experiments.Results: CBX7 expression significantly downregulated LUAD, which was associated with aberrant DNA methylation. Decreased CBX7 expression correlated with advanced tumor stage and poor prognosis. Notably, CBX7 is associated with immune cell infiltration and immune checkpoints, highlighting its potential role in guiding immunotherapy. Functional experiments demonstrated that CBX7 overexpression suppressed the malignant phenotype of LUAD cells, while CBX7 knockdown promoted tumor progression.Conclusion: We conducted a systematic analysis of the diagnostic, prognostic, and immunological significance of CBX7 in LUAD, and found that it might serve as a diagnostic marker and therapeutic target in the future.","PeriodicalId":10873,"journal":{"name":"Current molecular medicine","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665240374044250416021616","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chromobox 7 (CBX7) has been implicated in the progression of various malignant tumors, but its clinical relevance in lung adenocarcinoma (LUAD) remains poorly understood. This study aimed to investigate the expression, prognostic value, biological functions, and immunological role of CBX7 in LUAD.

Methods: CBX7 expression in LUAD and adjacent normal tissues was analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Kaplan-Meier curves and Cox risk regression evaluated prognostic significance. Various algorithms assessed the correlation between CBX7 and immune microenvironment. The expression of CBX7 in LUAD tissues was detected by RT-qPCR, western blotting, and immunohistochemistry. The function of CBX7 in LUAD was further investigated by in vitro and in vivo experiments.

Results: CBX7 expression significantly downregulated LUAD, which was associated with aberrant DNA methylation. Decreased CBX7 expression correlated with advanced tumor stage and poor prognosis. Notably, CBX7 is associated with immune cell infiltration and immune checkpoints, highlighting its potential role in guiding immunotherapy. Functional experiments demonstrated that CBX7 overexpression suppressed the malignant phenotype of LUAD cells, while CBX7 knockdown promoted tumor progression.

Conclusion: We conducted a systematic analysis of the diagnostic, prognostic, and immunological significance of CBX7 in LUAD, and found that it might serve as a diagnostic marker and therapeutic target in the future.

查看原文本刊更多论文

CBX7在肺腺癌中的预后价值及免疫学作用。

背景：染色体盒7 （CBX7）与多种恶性肿瘤的进展有关，但其在肺腺癌（LUAD）中的临床相关性仍知之甚少。本研究旨在探讨CBX7在LUAD中的表达、预后价值、生物学功能和免疫学作用。方法：使用Cancer Genome Atlas （TCGA）和Gene expression Omnibus （GEO）数据集分析CBX7在LUAD及邻近正常组织中的表达。Kaplan-Meier曲线和Cox风险回归评价预后意义。各种算法评估CBX7与免疫微环境之间的相关性。采用RT-qPCR、western blotting和免疫组化检测CBX7在LUAD组织中的表达。通过体外和体内实验进一步研究CBX7在LUAD中的作用。结果：CBX7表达显著下调LUAD，与异常DNA甲基化有关。CBX7表达降低与肿瘤分期晚期、预后不良相关。值得注意的是，CBX7与免疫细胞浸润和免疫检查点有关，突出了其在指导免疫治疗中的潜在作用。功能实验表明，CBX7过表达抑制LUAD细胞的恶性表型，而CBX7敲低促进肿瘤进展。结论：我们系统分析了CBX7在LUAD中的诊断、预后和免疫学意义，发现CBX7可能在未来作为诊断标志物和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current molecular medicine 医学-医学：研究与实验

CiteScore

5.00

自引率

4.00%

发文量

141

审稿时长

4-8 weeks

期刊介绍： Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews/ mini-reviews, original research articles, short communications/letters and drug clinical trial studies on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal invites guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.